Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis
View abstract on PubMed
Summary
This summary is machine-generated.Mesalamine reduces beta-catenin signaling in intestinal progenitor cells, potentially preventing colitis-associated cancer (CAC) by inhibiting Akt activation and P-beta-catenin. This finding supports mesalamine
Area Of Science
- Gastroenterology
- Molecular Biology
- Cancer Chemoprevention
Background
- Mesalamine is a key treatment for chronic ulcerative colitis (CUC), known to improve crypt architecture and reduce colitis-associated cancer (CAC).
- The study investigates mesalamine's role in modulating beta-catenin signaling, progenitor cell activation, and colitis-induced dysplasia (CID).
Purpose Of The Study
- To determine if mesalamine reduces beta-catenin-associated progenitor cell activation, specifically Akt-phosphorylated beta-catenin (P-beta-catenin).
- To assess mesalamine's effect on colitis-induced dysplasia (CID) and its underlying molecular mechanisms.
Main Methods
- Immunohistochemistry and qRT-PCR were used to analyze P-beta-catenin in CUC biopsy specimens.
- Epithelial proliferation, Akt, and beta-catenin activation were studied in IL-10(-/-) colitis and CID models using immunohistochemistry and Western blotting.
- Dysplasia was quantified by counting lesion number and length.
Main Results
- Mesalamine decreased Akt activation and P-beta-catenin levels in the middle and upper crypts of both IL-10(-/-) mice and human CUC samples.
- Reduced P-beta-catenin was observed in CUC biopsies with severe inflammation, indicating efficacy even in refractory tissue.
- In IL-10(-/-) mice, mesalamine treatment led to reduced CID, correlating with inhibited crypt Akt and beta-catenin signaling.
Conclusions
- Mesalamine's chemopreventive effect in colitis-associated cancer (CAC) is likely mediated by reducing beta-catenin signaling in intestinal progenitors.